Alexey Yakovlev

Mr. Alexey Yakovlev

ICBFM SB RAS
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
OBOlga Bryzgunova
Olga Bryzgunova
MKMaria Konoshenko
Maria Konoshenko
IZIvan A. Zaporozhchenko
Ivan A. Zaporozhchenko
AYAlexey Yakovlev
Alexey Yakovlev
PLPavel P. Laktionov
Pavel P. Laktionov
A vast wealth of recent research has seen attempts of using microRNA (miRNA) found in biological fluids in clinical research and medicine. One of the reasons behind this trend is the apparent their high stability of cell-free miRNA conferred by small size and packaging in supramolecular complexes. However, researchers in both basic and clinical settings often face the problem of selecting adequate methods to extract appropriate quality miRNA preparations for use in specific downstream analysis pipelines. This review outlines the variety of different methods of miRNA isolation from biofluids and examines the key determinants of their efficiency, including, but not limited to, the structural properties of miRNA and factors defining their stability in the extracellular environment.

1 January 2024 in ExRNA
Verified
Journal Article
Closed access
OBOlga Bryzgunova
Olga Bryzgunova
AYAlexey Yakovlev
Alexey Yakovlev
IOIlya Ostaltsev
Ilya Ostaltsev
PLPavel P. Laktionov
Pavel P. Laktionov
MKMaria Yurievna Konoshenko
Maria Yurievna Konoshenko
Aim: Current prostate cancer (PCa) diagnostics are based on PSA level assessment as well as histological analysis of biopsies. However, both false negative and false positive diagnoses are still made....

1 January 2024 in ExRNA
Verified
Journal Article
Open access
PDF file
OBOlga Bryzgunova
Olga Bryzgunova
AYAlexey Yakovlev
Alexey Yakovlev
IOIlya Ostaltsev
Ilya Ostaltsev
PLPavel P. Laktionov
Pavel P. Laktionov
MKMaria Konoshenko
Maria Konoshenko
Aim: Radical prostatectomy (RP) is the most frequent frontline PCa treatment. Biochemical recurrence (BCR) after radical prostatectomy occurs in 20%–40% of patients, but only 30% of these patients dem...